About the article
Most Recent
- Prion disease: Thorough w......Sporadic Creutzfeldt–Jakob disease (sCJD), the prototypical rapidly progressive dementia (RPD), is......read the complete article
- Diffusion-weighted MRI hy......Background: Diffusion-weighted imaging (DWI) and fluid-attenuated inversion recovery (FLAIR) ......read the complete article
- PrionsThe discovery of infectious proteins, denoted prions, was unexpected. After much debate over the che......read the complete article
- Pathologic evidence that ......Human prion diseases can be caused by mutations in the prion protein gene PRNP. Prion disease with m......read the complete article
- Variably protease-sensiti......Objective: The objective of the study is to report 2 new genotypic forms of protease-sensitiv......read the complete article
News & Articles
Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfolding
Many neurodegenerative disorders share common features including the accumulation of aggregated misfolded proteins, neuroinflammation and the induction of apoptosis. While the contributions of each of these individual elements to neuronal death remain unclear, a commonly used antibiotic, minocycline, has been shown to reduce the progression and severity of disease in several models of neurodegeneration by variously downregulating these molecular pathways. Here we discuss the evidence for the potential of minocycline as a broad-specificity therapeutic agent for those neurodegenerative diseases that are characterized by the presence of misfolded proteins.
Citation: Noble W, Garwood CJ, Hanger DP. Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfolding. Prion. 2009 Apr;3(2):78-83. Epub 2009 Apr 21.